Total Payments
$3,535
2024 Payments
$35.41
Companies
20
Transactions
197
Medicare Patients
15,232
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$3,466 (98.0%)
Education$69.70 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,466 | 196 | 98.0% |
| Education | $69.70 | 1 | 2.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $763.79 | 17 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $565.29 | 45 | $0 (2024) |
| PFIZER INC. | $564.06 | 40 | $0 (2022) |
| Merck Sharp & Dohme LLC | $460.15 | 21 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $275.53 | 16 | $0 (2022) |
| Gilead Sciences, Inc. | $204.98 | 16 | $0 (2019) |
| Amgen Inc. | $145.34 | 10 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $139.67 | 8 | $0 (2022) |
| Esperion Therapeutics, Inc. | $93.93 | 7 | $0 (2023) |
| Medtronic Vascular, Inc. | $74.10 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35.41 | 2 | Novartis Pharmaceuticals Corporation ($35.41) |
| 2023 | $491.35 | 32 | Merck Sharp & Dohme LLC ($206.90) |
| 2022 | $606.45 | 35 | Merck Sharp & Dohme LLC ($176.11) |
| 2021 | $547.66 | 38 | Novartis Pharmaceuticals Corporation ($159.77) |
| 2020 | $221.29 | 15 | SANOFI-AVENTIS U.S. LLC ($41.85) |
| 2019 | $237.12 | 15 | Abbott Laboratories ($63.35) |
| 2018 | $533.66 | 26 | Abbott Laboratories ($240.91) |
| 2017 | $862.35 | 34 | Abbott Laboratories ($369.31) |
All Payment Transactions
197 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/31/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/14/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $3.80 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/06/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/20/2023 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/16/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/08/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/12/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/11/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/21/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $5.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/07/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/22/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $7.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/10/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/02/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $8.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/31/2023 | Itamar Medical Inc | WatchPATONE (Device) | Food and Beverage | Cash or cash equivalent | $22.21 | General |
| Category: Sleep Apnea testing | ||||||
| 07/27/2023 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/20/2023 | Abbott Laboratories | QUADRA ASSURA (Device) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Cardiac Rhythm Management | ||||||
| 07/13/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/13/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $7.48 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $27.63 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.11 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/25/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $8.52 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/18/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.26 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/27/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.68 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/06/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 2,988 | 4,400 | $1.1M | $287,179 |
| 2022 | 29 | 3,771 | 6,000 | $1.5M | $361,840 |
| 2021 | 35 | 3,970 | 6,468 | $1.4M | $362,020 |
| 2020 | 37 | 4,503 | 7,073 | $1.7M | $399,368 |
Total Patients
15,232
Total Services
23,941
Medicare Billing
$1.4M
Procedure Codes
129
All Medicare Procedures & Services
129 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 659 | 1,123 | $189,124 | $62,944 | 33.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 449 | 469 | $343,664 | $57,683 | 16.8% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 171 | 171 | $178,740 | $52,016 | 29.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 434 | 558 | $105,820 | $44,780 | 42.3% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 117 | 465 | $46,505 | $20,061 | 43.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 86 | 88 | $37,915 | $10,938 | 28.8% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 159 | 191 | $103,350 | $10,788 | 10.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 176 | 176 | $44,840 | $7,945 | 17.7% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 25 | 25 | $11,060 | $3,813 | 34.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 306 | 329 | $28,565 | $2,801 | 9.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 40 | $3,951 | $2,354 | 59.6% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 51 | 65 | $8,765 | $1,615 | 18.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 13 | 15 | $2,875 | $1,481 | 51.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 27 | 27 | $15,272 | $1,358 | 8.9% |
| 85610 | Blood test, clotting time | Office | 2023 | 47 | 305 | $6,120 | $1,281 | 20.9% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 43 | 56 | $4,600 | $1,203 | 26.1% |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | Office | 2023 | 65 | 128 | $1,540 | $1,176 | 76.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 19 | 20 | $2,344 | $704.61 | 30.1% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 20 | 26 | $4,240 | $667.44 | 15.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 26 | 31 | $1,838 | $457.65 | 24.9% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 28 | 31 | $2,900 | $430.47 | 14.8% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 21 | 21 | $1,660 | $375.90 | 22.6% |
| 93040 | Electrocardiogram (ecg) 1 to 3 leads with review by physician | Office | 2023 | 23 | 40 | $1,432 | $306.20 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 871 | 1,601 | $160,100 | $89,898 | 56.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 520 | 547 | $679,363 | $68,953 | 10.1% |
About Dr. Eva Magiros, M.D
Dr. Eva Magiros, M.D is a Cardiovascular Disease healthcare provider based in Biloxi, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033168091.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eva Magiros, M.D has received a total of $3,535 in payments from pharmaceutical and medical device companies, with $35.41 received in 2024. These payments were reported across 197 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($3,466).
As a Medicare-enrolled provider, Magiros has provided services to 15,232 Medicare beneficiaries, totaling 23,941 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 129 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Biloxi, MS
- Active Since 05/08/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1033168091
Products in Payments
- ELIQUIS (Drug) $460.26
- VERQUVO (Drug) $460.15
- ENTRESTO (Drug) $333.60
- XARELTO (Drug) $275.53
- CRT-Ds (Device) $243.66
- LEQVIO (Drug) $231.69
- Quadra Assura CRT Defibrillator (Device) $160.03
- MULTAQ (Drug) $110.27
- Repatha (Biological) $103.79
- NEXLETOL (Drug) $93.93
- Supera peripheral stent system (Device) $86.34
- CHANTIX (Drug) $78.56
- Merlin Connectivity and Remote (Device) $70.19
- Confirm Rx (Device) $63.35
- HawkOne (Device) $62.96
- VIAGRA (Drug) $58.31
- MERLIN@HOME (Device) $55.44
- CardioMEMS HF System (Device) $47.61
- Corlanor (Drug) $41.55
- PRALUENT (Drug) $29.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Biloxi
Antoine Rizk, M.d, M.D
Cardiovascular Disease — Payments: $38,463
Cardiovascular Disease $38,463
Paul Mullen, M.d, M.D
Cardiovascular Disease — Payments: $36,368
Cardiovascular Disease $36,368
Jack Brand, Md, MD
Cardiovascular Disease — Payments: $7,173
Cardiovascular Disease $7,173
Dr. Gilberto Patino, Md, MD
Cardiovascular Disease — Payments: $2,210
Cardiovascular Disease $2,210
Dr. Alexander Yuan, D.o, D.O
Cardiovascular Disease — Payments: $202.90
Cardiovascular Disease $202.90